NASDAQ:ALLK

Allakos (ALLK) Stock Forecast, Price & News

$4.94

-0.19 (-3.70%)

(As of 06/6/2023 ET)

Compare

Today's Range: $4.92
▼
$5.15
50-Day Range: $3.60
▼
$5.25
52-Week Range: $2.54
▼
$8.73

Volume: 855,264 shs
Average Volume: 1.03 million shs
Market Capitalization: $427.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.60

Allakos MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 175.3% Upside
$13.60 Price Target
Short Interest: Healthy
8.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.86
Upright™ Environmental Score
News Sentiment: 0.72
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.99) to ($1.93) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

85th out of 981 stocks

Pharmaceutical Preparations Industry

30th out of 464 stocks

3.3

Analyst's Opinion

Consensus Rating
Allakos has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $13.60, Allakos has a forecasted upside of 175.3% from its current price of $4.94.
Amount of Analyst Coverage
Allakos has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
8.34% of the float of Allakos has been sold short.
Short Interest Ratio / Days to Cover
Allakos has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Allakos has recently decreased by 12.58%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Allakos does not currently pay a dividend.
Dividend Growth
Allakos does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Allakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Allakos is -0.86.

3.2

News and Social Media Coverage

News Sentiment
Allakos has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Allakos this week, compared to 2 articles on an average week.
Search Interest
Only 12 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
4 people have added Allakos to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Allakos insiders have not sold or bought any company stock.
Percentage Held by Insiders
33.25% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
93.07% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Allakos are expected to grow in the coming year, from ($1.99) to ($1.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Allakos is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Allakos is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Allakos has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Allakos (NASDAQ:ALLK) Stock

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

June 5, 2023 | finance.yahoo.com

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

May 31, 2023 | benzinga.com

Board Member at Allakos Acquires Company Stock Options Worth 86,762 Shares

June 6, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 30, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Sees Significant Decline in Short Interest

May 28, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Receives Consensus Rating of "Moderate Buy" from Analysts

May 26, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 25, 2023 | americanbankingnews.com

Allakos (NASDAQ:ALLK) vs. Homology Medicines (NASDAQ:FIXX) Financial Survey

May 16, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Sees Significant Increase in Short Interest

June 6, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Software" to Revolutionize Warfare

This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>

May 14, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Forecasted to Earn Q2 2023 Earnings of ($0.51) Per Share

May 14, 2023 | americanbankingnews.com

Allakos (NASDAQ:ALLK) Rating Increased to Buy at Jefferies Financial Group

May 13, 2023 | finance.yahoo.com

Allakos Inc. (NASDAQ:ALLK) has caught the attention of institutional investors who hold a sizeable 45% stake

May 12, 2023 | msn.com

Jefferies Upgrades Allakos (ALLK)

May 12, 2023 | finance.yahoo.com

Why Allakos Stock Skyrocketed Nearly 9% Higher Today

May 12, 2023 | au.investing.com

Allakos upgraded as Jefferies sees favorable setup

May 12, 2023 | msn.com

Analyst Ratings for Allakos

May 11, 2023 | msn.com

Allakos: Q1 Earnings Insights

May 10, 2023 | finanznachrichten.de

Allakos Inc.: Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

May 10, 2023 | markets.businessinsider.com

LifeSci Capital Keeps Their Buy Rating on Allakos (ALLK)

May 9, 2023 | finance.yahoo.com

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

April 29, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Receives $14.75 Average PT from Analysts

April 23, 2023 | ca.finance.yahoo.com

Allakos Inc. (ALLK) Stock Historical Prices & Data - Yahoo Finance

April 21, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Short Interest Update

April 4, 2023 | americanbankingnews.com

Allakos Inc. (NASDAQ:ALLK) Receives $14.75 Consensus Price Target from Brokerages

March 10, 2023 | msn.com

Where Allakos Stands With Analysts

March 10, 2023 | msn.com

Why Allakos Stock Was Heating Up Today

March 6, 2023 | finance.yahoo.com

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

See More Headlines

ALLK Price History

30 days | 90 days | 365 days | Advanced Chart

ALLK Company Calendar

Last Earnings: 5/09/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALLK
CUSIP: N/A
CIK: 1564824
Web: www.allakos.com
Phone: (650) 597-5002
Fax: N/A
Employees: 192
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.60
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +173.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-319,950,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -57.12%
Return on Assets: -45.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.58
Quick Ratio: 9.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.64 per share
Price / Book: 1.37

Miscellaneous

Outstanding Shares: 86,560,000
Free Float: 57,779,000
Market Cap: $431.07 million
Optionable: Not Optionable
Beta: 0.44

Key Executives

Robert Alexander
Chief Executive Officer & Director

Adam L. Tomasi
President

Harlan Baird Radford
Chief Financial Officer

Craig Paterson
Chief Medical Officer

Brad Youngblood
Head-Research & Pre-Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALLK shares.
View ALLK analyst ratings or view top-rated stocks.
What is Allakos' stock price forecast for 2023?: 6 Wall Street analysts have issued 12-month target prices for Allakos' stock. Their ALLK share price forecasts range from $7.00 to $22.00. On average, they predict the company's share price to reach $13.60 in the next year. This suggests a possible upside of 173.1% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.
How have ALLK shares performed in 2023?: Allakos' stock was trading at $8.42 at the beginning of 2023. Since then, ALLK stock has decreased by 40.9% and is now trading at $4.98.
View the best growth stocks for 2023 here.
Are investors shorting Allakos?: Allakos saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,310,000 shares, a drop of 12.6% from the April 30th total of 4,930,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 3.7 days. Currently, 8.3% of the shares of the company are sold short.
View Allakos' Short Interest.
When is Allakos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ALLK earnings forecast.
How were Allakos' earnings last quarter?: Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49).
What ETFs hold Allakos' stock?: ETFs with the largest weight of Allakos (NASDAQ:ALLK) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA SmallCap Momentum ETF (DWAS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ProShares Ultra Nasdaq Biotechnology (BIB), BlackRock Future Health ETF (BMED),
What other stocks do shareholders of Allakos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?: (ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.
What is Allakos' stock symbol?: Allakos trades on the NASDAQ under the ticker symbol "ALLK."
Who are Allakos' major shareholders?: Allakos' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (7.00%), Logos Global Management LP (6.40%), State Street Corp (4.42%), BlackRock Inc. (2.95%), Commodore Capital LP (2.20%) and Federated Hermes Inc. (1.76%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends.
How do I buy shares of Allakos?: Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Allakos' stock price today?: One share of ALLK stock can currently be purchased for approximately $4.98.
How much money does Allakos make?: Allakos (NASDAQ:ALLK) has a market capitalization of $431.07 million. The company earns $-319,950,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.
How many employees does Allakos have?: The company employs 192 workers across the globe.
How can I contact Allakos?: Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial